OPEN ACCESS Freely available online

ISSN: 2375-4516
Intellectual Property Rights: Open Access

Commentary

Role of Copyright Abolition in the Development of Drug Discovery

Christiono Rahmawati*

Department of Biomedical Convergence, Chungbuk National University, Cheongju, South Korea

DESCRIPTION

The interplay between intellectual property rights and scientific progress is the subject of considerable debate in the field of drug discovery. Central to this debate is the copyright system, which has historically governed the ownership and dissemination of scientific works. However, an emerging debate argues for copyright abolition or reform in this field, recognizing that such measures can catalyse innovation while also meeting public health needs. Copyright emerged as part of broader intellectual property law intended to promote creativity by granting creators exclusive rights to their works for a limited time. In the United States, the Copyright Act of 1976, along with the Berne Convention, established the modern framework in which authors own the rights to their original creations, including scientific literature. In the field of drug discovery, this typically includes research publications, clinical data and patentable inventions. However, the landscape began to change as the drug development process became increasingly complex and inequitable access to essential medicines became recognized.

The late 20th century saw the emergence of several prominent advocates for reform. In addition, organizations such as Médecins Sans Frontières have campaigned tirelessly against the monopolies created by the copyright and patent systems, highlighting the plight of those who are saddled with high drug costs due to exclusive rights to drug formulation and research. Their work highlights the need for open access models that propose that research results be accessible to the public without barriers.

Advocates for de-copyrighting drug discovery argue that the current system stifles innovation rather than promotes it. They argue that the monopolistic nature of copyright leads to high prices for essential drugs because pharmaceutical companies are motivated to maximize profits rather than prioritizing therapeutic efficacy or accessibility. Antiretroviral therapy for HIV/AIDS is often cited, for example; patented drugs remain expensive, limiting access in low-income countries. Abolition of copyright could enable collaborative, open-source approaches to drug discovery, facilitate knowledge sharing across institutions and spur rapid advances in therapeutics. Conversely, critics of the abolitionist perspective warn of the unintended consequences of such a reform. If the potential for recovery through patents is reduced or eliminated, this could lead to less funding for new innovations, leading to fewer therapeutic breakthroughs.

The tensions surrounding deregulation raise important ethical considerations. The framework must also address the issue of transparency in research. A move toward deregulation could lead to increased sharing of data and results, seemingly lowering barriers to drug discovery. Conversely, monopoly models often limit access to important research, maintaining silos of knowledge that hinder collaborative efforts. French Such transparency could accelerate development, especially in response to urgent public health crises, such as the COVID-19 pandemic, where rapid innovation has become important. Given the complexities associated with copyright in drug discovery, common platforms may be more beneficial than outright abolition. Initiatives that encourage open access publishing, data sharing and public funding of research could balance the need to encourage innovation while improving access to essential medicines. Models such as the Creative Commons framework, which allow certain rights to be maintained while promoting knowledge sharing, suggest a potential path forward.

In summary, the debate over the abolition of copyright in drug discovery represents an important intersection between science, ethics and public health. Historical developments inform the current discourse, highlighting the contributions of influential individuals and organizations in driving reform. While there are compelling arguments on both sides – in favor of open access and highlighting the risks of reducing incentives–it is essential to recognize the nuances of this debate. A potential compromise, one that integrates elements of both open access and proprietary systems, could pave the way for drug discovery to advance public health priorities while supporting research innovation.

Correspondence to: Christiono Rahmawati, Department of Biomedical Convergence, Chungbuk National University, Cheongju, South Korea, E-mail: christiono@rahmawati.com

Received: 30-Aug-2024, Manuscript No. IPR-25-28427; **Editor assigned:** 02-Sep-2024, PreQC No. IPR-25-28427 (PQ); **Reviewed:** 16-Sep-2024, QC No. IPR-25-28427; **Revised:** 23-Sep-2024, Manuscript No. IPR-25-28427 (R); **Published:** 30-Sep-2024, DOI: 10.35248/2375-4516.24.12.267

Citation: Rahmawati C (2024). Role of Copyright Abolition in the Development of Drug Discovery. Intel Prop Rights. 12:267.